RCC
Oncology · 2006–2024
42decisions
14medicines
17carried consumer input
37individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Multiple cancer indications: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small… | Mar 2024 | Recommended | 1 individuals Medical Oncology Group |
| cabozantinib Treatment of non-clear cell renal cell carcinoma (nccRCC) in treatment-naïve adults with intermediate or poor risk and in adults following prior treatment with… | Mar 2024 | Recommended with restriction | input received ANZUP Cancer Trials Group · Rare Cancers Australia · Medical Oncology Group |
| cabozantinib First-line treatment of advanced (Stage IV) clear cell variant renal cell carcinoma in patients classified as intermediate or poor risk according to the… | Mar 2024 | Recommended with restriction | input received Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab Adjuvant treatment of patients with renal cell carcinoma (RCC) with clear cell component who are at intermediate-high or high risk of recurrence following… | Nov 2024 | Recommended with restriction | 4 individuals Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab First-line treatment of advanced (Stage IV) clear cell variant renal cell carcinoma in patients classified as intermediate or poor risk according to IMDC… | Mar 2022 | Recommended with restriction | input received Medical Oncology Group |
| avelumab First-line treatment of advanced (stage IV) clear cell variant renal cell carcinoma in patients classified as intermediate or poor risk according to IMDC… | Mar 2021 | Recommended with restriction | unclear |
| avelumab First-line treatment of advanced (stage IV) clear cell variant renal cell carcinoma in patients with intermediate to poor prognostic risk according to IMDC… | Mar 2020 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group |
| cabozantinib Stage IV clear cell variant advanced renal cell carcinoma (RCC) with intermediate to poor risk classification according to IMDC criteria, in patients who have… | Mar 2020 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group |
| cabozantinib Stage IV clear cell variant advanced renal cell carcinoma (RCC) with intermediate to poor risk classification according to IMDC criteria in patients who have… | Nov 2020 | Recommended with restriction | input received Medical Oncology Group |
| cabozantinib First-line treatment of Stage IV clear cell variant renal cell carcinoma in patients meeting IMDC criteria for intermediate to poor risk disease. | Mar 2019 | Not recommended | unclear |
| nivolumab + ipilimumab First-line treatment of Stage IV clear cell variant renal cell carcinoma in patients with intermediate to poor prognostic risk according to the International… | Jul 2018 | Not recommended | 7 individuals Medical Oncology Group |
| lenvatinib Treatment of patients with stage IV clear cell variant renal cell carcinoma (RCC) who have progressed after first-line treatment with a tyrosine kinase… | Mar 2018 | Not recommended | none received |
| nivolumab First-line treatment of Stage IV clear cell variant renal cell carcinoma (RCC) in patients meeting the International Metastatic Renal Cell Carcinoma Database… | Nov 2018 | Recommended with restriction | input received Medical Oncology Group |
| nivolumab Treatment of Stage IV clear cell variant renal cell carcinoma (RCC) in patients who have progressed according to RECIST following first-line treatment with a… | Mar 2017 | Recommended with restriction | 4 individuals Medical Oncology Group |
| cabozantinib Treatment of patients with Stage IV (unresectable) clear cell variant renal cell carcinoma (RCC) who have progressive disease following first-line treatment… | Dec 2017 | Recommended with restriction | 1 individuals |
| lenvatinib Stage IV clear cell variant renal cell carcinoma in patients with disease progression following first-line tyrosine kinase inhibitor therapy, used in… | Nov 2017 | Not recommended | none received |
| nivolumab Treatment of advanced or metastatic clear cell variant renal cell carcinoma (RCC) in patients who have progressed following first-line treatment with a… | Jul 2016 | Not recommended | 1 individuals |
| nivolumab Second-line treatment of Stage IV clear cell variant renal cell carcinoma (RCC) in patients with progressive disease following first-line tyrosine kinase… | Nov 2016 | Not recommended | 7 individuals |
| everolimus Stage IV clear cell variant renal cell carcinoma (RCC) after progression on tyrosine kinase inhibitor therapy. | Mar 2014 | Recommended with restriction | 2 individuals |
| axitinib Second-line treatment of stage IV clear cell variant renal cell carcinoma (RCC) in patients with progressive disease following first-line tyrosine kinase… | Nov 2014 | Recommended | 6 individuals |
| sorafenib Second-line treatment of stage IV clear cell variant renal cell carcinoma (RCC) in patients who have failed first-line treatment with a tyrosine kinase… | Nov 2014 | Recommended | 4 individuals |
| axitinib Second-line treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO performance status of 2 or less where disease progression has… | Nov 2013 | Not recommended | no section in document |
| sorafenib Stage IV (advanced) clear cell variant renal cell carcinoma (RCC) in patients who have failed first-line therapy with sunitinib or pazopanib, as second-line… | Nov 2013 | Not recommended | unclear |
| pazopanib Initial and continuing treatment of stage IV clear cell variant renal cell carcinoma (RCC) in newly diagnosed patients meeting MSKCC low to intermediate risk… | Mar 2012 | Recommended with restriction | no section in document |
| pazopanib Initial and continuing treatment of stage IV clear cell variant renal cell carcinoma (RCC) in newly diagnosed patients meeting Memorial Sloan Kettering Cancer… | Mar 2012 | Recommended with restriction | no section in document |
| sorafenib Initial and continuing treatment of Stage IV clear cell renal carcinoma in patients who have failed first-line therapy and meet MSKCC risk group and… | Nov 2012 | Recommended | no section in document |
| sorafenib Initial and continuing treatment of Stage IV clear cell renal carcinoma in patients who have failed first-line therapy and meet MSKCC risk criteria. | Nov 2012 | Recommended | no section in document |
| everolimus Initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO status 2 or less who have failed treatment with… | Nov 2011 | Not recommended | unclear |
| everolimus Initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO status of 2 or less who have failed treatment with… | Nov 2011 | Not recommended | unclear |
| everolimus Initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO status 2 or less who have progressive disease on… | Jul 2010 | Not recommended | no section in document |
| pazopanib Stage IV advanced and/or metastatic, clear cell variant renal cell carcinoma (RCC) in adult patients meeting Memorial Sloan Kettering Cancer Centre low to… | Jul 2010 | Not recommended | no section in document |
| everolimus Initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO status ≤2 who have progressive disease on sunitinib… | Jul 2010 | Not recommended | no section in document |
| pazopanib Treatment of stage IV advanced and/or metastatic, clear cell variant renal cell carcinoma (RCC) in adult patients. | Jul 2010 | Not recommended | no section in document |
| everolimus Treatment of patients with Stage IV clear cell variant renal cell carcinoma after failure of treatment with sorafenib or sunitinib. | Nov 2009 | Not recommended | no section in document |
| sunitinib malate Treatment of advanced (unresectable or metastatic) renal cell carcinoma (RCC) in patients with ECOG performance status of 0 or 1. | Jul 2008 | Recommended with restriction | no section in document |
| temsirolimus Advanced renal cell carcinoma in patients with poor prognosis who meet defined criteria (at least three of six poor prognostic factors). | Jul 2008 | Recommended | no section in document |
| sorafenib tosylate Initial and continuing treatment of advanced (unresectable or metastatic) renal cell carcinoma in patients with WHO performance status 2 or less, where the… | Mar 2008 | Not recommended | no section in document |
| sunitinib malate Treatment of advanced (unresectable or metastatic) renal cell carcinoma (RCC) in patients with Eastern Cooperative Oncology Group (ECOG) performance status of… | Mar 2008 | Not recommended | no section in document |
| sunitinib malate Advanced renal cell carcinoma (RCC), specifically Stage IV disease with clear cell histology as first-line therapy. | Mar 2007 | Deferred | no section in document |
| sunitinib malate Treatment of advanced renal cell carcinoma (RCC) as first-line therapy in patients with advanced/metastatic disease. | Mar 2007 | Deferred | no section in document |
| sorafenib tosylate Initial and continuing treatment of advanced (unresectable or metastatic) renal cell carcinoma in patients with WHO performance status of 2 or less. | Nov 2006 | Recommended | no section in document |
| sorafenib tosylate Initial and continuing treatment of advanced (unresectable or metastatic) renal cell carcinoma in patients with WHO performance status of 2 or less. | Nov 2006 | Recommended | no section in document |
Who spoke
Medical Oncology Group · Rare Cancers Australia · ANZUP Cancer Trials Group
What the PBS pays
$1,221M in government benefit over 2024–25, across 162,040 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| nivolumab + ipilimumab | $199M |
| nivolumab | $85.2M |
| avelumab | $71.8M |
| cabozantinib | $55.8M |
| lenvatinib | $31.4M |
| everolimus | $23M |
| pazopanib | $9.1M |
| axitinib | $4.3M |
| sorafenib | $0.7M |
| sorafenib tosylate | $0.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 17 technologies for this condition, recommending 14 and declining 2. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| avelumabAvelumab with axitinib for untreated advanced renal cell carcinoma | TA1120 | recommended restricted | 2026-01 |
| cabozantinibCabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | recommended restricted | 2024-04 |
| lenvatinibLenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | recommended restricted | 2023-01 |
| pembrolizumabPembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | recommended restricted | 2022-10 |
| nivolumabNivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | terminated | 2022-04 |
| nivolumabNivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | recommended | 2022-03 |
| pembrolizumabPembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | not recommended | 2020-09 |
| cabozantinibCabozantinib for untreated advanced renal cell carcinoma | TA542 | recommended restricted | 2018-10 |
| tivozanibTivozanib for treating advanced renal cell carcinoma | TA512 | recommended restricted | 2018-03 |
| lenvatinibLenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | recommended restricted | 2018-01 |
| cabozantinibCabozantinib for previously treated advanced renal cell carcinoma | TA463 | recommended restricted | 2017-08 |
| everolimusEverolimus for advanced renal cell carcinoma after previous treatment | TA432 | recommended restricted | 2017-02 |
Showing the 12 most recent of 17.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 17 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.